One-Year Outcomes After Everolimus-Eluting Stents Implantation in Ostial Lesions of Left Anterior Descending Coronary Arteries.
| Autor: | Golmohamadi Z; Cardiovascular Research Center, Shaheed Madani Heart Hospital, Medical Science University, Tabriz, Iran., Sokhanvar S; Ayatollah Mosavi Cardiology Department, Medical Science University, Zanjan, Iran., Aslanabadi N; Cardiovascular Research Center, Shaheed Madani Heart Hospital, Medical Science University, Tabriz, Iran., Ghaffari S; Cardiovascular Research Center, Shaheed Madani Heart Hospital, Medical Science University, Tabriz, Iran., Sohrabi B; Cardiovascular Research Center, Shaheed Madani Heart Hospital, Medical Science University, Tabriz, Iran. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cardiology research [Cardiol Res] 2013 Dec; Vol. 4 (6), pp. 192-198. Date of Electronic Publication: 2014 Jan 02. |
| DOI: | 10.4021/cr295w |
| Abstrakt: | Background: In recent years, stents are increasingly used in variety of coronary lesions. Ostial lesion of left anterior descending coronary artery (LAD) however remains a challenge area because of the invariable involvement of distal left main coronary artery (LMCA). This study was designed to evaluate the clinical and angiographic outcomes of everolimus-eluting stent (EES) implantation for ostial LAD. Methods: EESs were implanted in 45 consecutive patients with ostial LAD stenoses. For complete lesion coverage, stent positing was extended into the distal LMCA in 6 patients (13.3%) with intermediated LMCA narrowing. We assess MACE during one-year follow-up. Results: In-hospital success rate was 100%; neither cardiac death nor stent thrombosis in our patients, but two patients had myocardial infarction in non-related coronary artery during follow-up. Two patients had angiographic restenosis and underwent TLR. The cumulative MACE-free survival rate was 95.6% at one year. Conclusion: EES was in ostial LAD lesions with complete lesion coverage achieving high procedural success rate and acceptable clinical outcomes during one-year follow-up period. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|